DALLAS, May 18 /PRNewswire-FirstCall/ -- HemoBioTech, Inc. announced today that Texas Tech University filed a patent application for induction of erythropoiesis (red blood cell production) by HemoTech(TM), a novel chemically modified hemoglobin. HemoBioTech has a worldwide exclusive license to HemoTech(TM), which is being developed as a blood substitute.
"We are very excited about the erythropoietic property of HemoTech(TM)," said Dr. Arthur P. Bollon, Chairman and CEO of HemoBioTech. "There is a strong interest in new agents which increase the level of red blood cells in patients. The development of a blood substitute that not only carries oxygen, but also increases the level of red blood cells, could have broad applications in medicine, especially trauma, elective surgery, acute anemia, cancer and heart disease."
HemoTech(TM) is created using a unique patented technology. Hemoglobin is polymerized with adenosine and ATP and is modified with glutathione. This chemistry results in an oxygen carrier which appears to be non-toxic, vasodilatory, anti-inflammatory and induces erythropoiesis based on an initial foreign clinical study. The new patent application filed for HemoTech(TM) describes its use and mechanism of action for induction of erythropoiesis as a treatment for blood loss.
HemoTech(TM) is under commercial development by HemoBioTech which has a sponsored research agreement with Texas Tech University Health Sciences Center (TTUHSC). Dr. Jan Simoni, who is an inventor of HemoTech(TM) and Associate Clinical Professor at TTUHSC, is Acting Vice President of R&D and Advisor to HemoBioTech. Dr. Mario Feola, who is also an inventor of HemoTech(TM), is Chief Medical Officer at HemoBioTech.
About HemoBioTech, Inc.
HemoBioTech is engaged in the commercial development of HemoTech(TM), a novel human blood substitute technology exclusively licensed from Texas Tech University Health Sciences Center. HemoTech(TM) is chemically modified bovine hemoglobin, which not only carries oxygen in the blood, but can also induce erythropoiesis (red blood cell production). The Company believes that HemoTech(TM) may possess properties that diminish the intrinsic toxicities which have plagued other attempts at developing blood substitutes, based upon pre-clinical and initial human clinical trials undertaken outside the U.S. by prior holders of this technology. HemoTech(TM) is being subjected to further studies and testing to confirm and possibly expand on these results. HemoTech(TM) is being developed to help reduce or eliminate the danger resulting from acute blood loss in trauma, as well as for other conditions. Corporate headquarters are located at J. P. Morgan International Plaza, 14221 Dallas Parkway, Suite 1400, Dallas, Texas 75254. For further information contact Dr. Arthur Bollon at 214-540-8411 or arthurb@flash.net . The Company website is http://www.hemobiotech.com .
Safe Harbor Statement
Except for historical information, the matters discussed in this news release may be considered "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of HemoBioTech and its management and are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a difference include, among others the successful pre- clinical development, the successful completion of clinical trials, the FDA review process and other governmental regulation, pharmaceutical collaborator interest and ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third party reimbursement, and other factors which are included in HemoBioTech's Annual Report on Form 10-KSB for the year ended December 31, 2005, as amended, and HemoBioTech's other reports filed with the Securities and Exchange Commission.
HemoBioTech, Inc.CONTACT: Dr. Arthur Bollon of HemoBioTech, Inc., +1-214-540-8411, orarthurb@flash.net
Web site: http://www.hemobiotech.com/
